Seeking Alpha

Abbott Laboratories (ABT)

  • Apr. 17, 2012, 4:10 PM
    Abbott Labs (ABT) says the results from its Phase 3 trial evaluating levodopa-carbidopa intestinal gel, its investigational compound for advanced Parkinson's disease, showed that patients reported clinically meaningful and statistically significant improvements compared to levodopa-carbidopa immediate release tablets.
    | Comment!
  • Apr. 11, 2012, 12:34 PM
    Abbott Laboratories' (ABT +0.4%) top-selling arthritis drug Humira is approved in Europe for moderate to severe ulcerative colitis. The decision makes Humira the first and only self-injectable biologic therapy for ulcerative colitis, and marks the seventh indication for the therapy in the EU since the product's first approval in 2003.
    | 1 Comment
  • Apr. 4, 2012, 12:48 PM
    Shares of Idenix Pharmaceuticals (IDIX -12.2%) sink after Abbott Laboratories (ABT +0.6%) releases positive results from studies of its experimental hepatitis C treatment. Other Hep-C companies vying for a piece of the rapidly-growing multi-billion dollar market: Gilead Sciences (GILD -2.2%), Vertex Pharmaceuticals (VRTX -1.2%), Bristol-Myers Squibb (BMY -0.5%), BioCryst Pharmaceuticals (BCRX -3.4%).
    | 1 Comment
  • Apr. 4, 2012, 12:36 PM
    Abbott Laboratories (ABT +0.5%) announces that studies of its experimental hepatitis C drug showed it suppressed the virus in most patients. If further studies follow through with positive results, the company plans to launch a new hepatitis C regimen in 2015.
    | Comment!
  • Mar. 28, 2012, 6:23 PM
    Myriad Genetics (MYGN) signs an agreement with Cephalon, a subsidiary of Teva Pharmaceutical (TEVA), to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study. Myriad has entered into similar agreements with Abbott (ABT), Astra Zeneca (AZN) and BioMarin (BMRN) to provide similar diagnostic testing.
    | Comment!
  • Mar. 27, 2012, 10:00 AM
    The upcoming division of Abbott Laboratories (ABT +0.4%) into two companies will lead to a run on shares prior to the split, according to John Mylant. He sees investors getting drawn in by the combination of catching an income producer (Abbvie) and a growth stock (Abbott) with one trade.
    | 1 Comment
  • Mar. 21, 2012, 10:07 AM
    Abbott Laboratories (ABT -0.3%) announces a new research pharmaceutical company that it expects to launch by the end of FY12 as part of its previously announced split. Called AbbVie, the new company will include Abbott's current portfolio of proprietary pharmaceuticals and biologics. The medical products company company will keep the Abbott name.
    | Comment!
  • Mar. 20, 2012, 12:08 PM
    The Supreme Court's decision to reject Prometheus Labs' (NSRGY.PK) testing patents has wider industry implications and could be a setback for other biotechs that sell diagnostic devices, including Roche (RHHBY.PK), Abbot (ABT +0.3%) and Myriad Genetics (MYGN -5.4%)
    | Comment!
  • Mar. 19, 2012, 3:14 PM
    Abbott Labs (ABT +1.4%) hits a three-year high as Deutsche Bank hikes its rating to Buy, arguing shares should climb ahead of the planned split of ABT’s drug unit from the rest of the company. Pharma could be worth $36/share by year-end 2012, the firm says, while the faster-growing medical products business could carry a value of $31/share.
    | Comment!
  • Mar. 15, 2012, 12:10 PM
    Wells Fargo says that Abbott Labs (ABT +0.6%) should continue to rally over the near-term, having already outperformed the S&P since the company announced a deal involving its oral JAK inhibitor for arthritis in late February. Wells expects momentum to continue, anticipating that positive data for the company's oral HCV treatment will provide an additional catalyst in April.
    | Comment!
  • Mar. 8, 2012, 1:30 PM
    Abbott Laboratories (ABT +2.4%) trades higher after receiving FDA clearance to sell its FreeStyle InsuLinx system for monitoring blood glucose levels. InsuLinx, which is already available for sale in Canada and several European countries, is the first glucose monitoring system from Abbott to feature a touchscreen and automated logbook.
    | Comment!
  • Mar. 7, 2012, 4:58 PM
    Eight big drugmakers - ABT, AMGN, AZN, BMY, GSK, MRK, NVS, PFE - are sued by a consumer group claiming the companies’ coupon programs, which cover much of the patient co-payment for hundreds of brand-name prescription medicines, are illegal.
  • Mar. 2, 2012, 10:36 AM
    Watson Pharmaceuticals (WPI -0.3%) confirms that it launched a generic version of Prometrium as part of an agreement with Abbott Laboratories (ABT +0.1%). Over the last 12-month reporting period, Prometrium had sales of close to $198M.
    | Comment!
  • Feb. 29, 2012, 7:45 AM
    Galapagos CEO Onno van de Stolpe calls the development deal with Abbott Laboratories (ABT) announced earlier today the "largest Phase 2 deal in the history of the industry." The agreement will line up Abbott in competition with Pfizer (PFE) in a race to develop a widely used rheumatoid arthritis drug. Shares of Galapagos are up 22% in Brussels trading.
  • Feb. 29, 2012, 5:07 AM
    Belgian drug developer Galapagos signs a deal worth up to $1.35B with Abbott Laboratories (ABT) for the development and production of an oral drug to treat arthritis and other auto-immune diseases. (PR)
    | Comment!
  • Feb. 21, 2012, 10:53 AM
    The Supreme Court rejects a request from Johnson & Johnson (JNJ -0.1%) to reinstate a $1.67B court ruling against Abbott Laboratories (ABT -0.4%) in a patent infringement case related to its Humira treatment for arthritis that contributes close to 20% of ABT's annual revenue.
    | Comment!
Visit Seeking Alpha's
ABT vs. ETF Alternatives
Company Description
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.